Tcr2 Therapeutics Alpha and Beta Analysis
| TCRRDelisted Stock | USD 1.48 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Tcr2 Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Tcr2 Therapeutics over a specified time horizon. Remember, high Tcr2 Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Tcr2 Therapeutics' market risk premium analysis include:
Beta 2.29 | Alpha 0.18 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Tcr2 |
Tcr2 Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Tcr2 Therapeutics market risk premium is the additional return an investor will receive from holding Tcr2 Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Tcr2 Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Tcr2 Therapeutics' performance over market.| α | 0.18 | β | 2.29 |
Tcr2 Therapeutics Fundamentals Vs Peers
Comparing Tcr2 Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Tcr2 Therapeutics' direct or indirect competition across all of the common fundamentals between Tcr2 Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Tcr2 Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Tcr2 Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Tcr2 Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Tcr2 Therapeutics to competition |
| Fundamentals | Tcr2 Therapeutics | Peer Average |
| Return On Equity | -0.91 | -0.31 |
| Return On Asset | -0.35 | -0.14 |
| Current Valuation | (73.69 M) | 16.62 B |
| Shares Outstanding | 39.26 M | 571.82 M |
| Shares Owned By Insiders | 1.50 % | 10.09 % |
| Shares Owned By Institutions | 54.31 % | 39.21 % |
| Number Of Shares Shorted | 360.89 K | 4.71 M |
Tcr2 Therapeutics Opportunities
Tcr2 Therapeutics Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | What To Know About Jefferiess Downgrade of TCR2 Therapeutics - TCR2 Therapeutics - Benzinga | 03/09/2023 |
2 | Tcr2 Therapeutics earnings missed by 0.76, revenue was in line with estimates | 03/23/2023 |
3 | TCR Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 04/03/2023 |
4 | Tcr2 Therapeutics exotic insider transaction detected | 05/05/2023 |
5 | Purchase by Tang Kevin C of 57073 shares of Tcr2 Therapeutics | 05/10/2023 |
6 | TCR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update | 05/11/2023 |
7 | TCR2 Therapeutics Insider Trades Send a Signal | 05/16/2023 |
8 | Purchase by Tang Kevin C of 50000 shares of Tcr2 Therapeutics | 05/30/2023 |
About Tcr2 Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Tcr2 or other delisted stocks. Alpha measures the amount that position in Tcr2 Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Tcr2 Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Tcr2 Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tcr2 Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Tcr2 Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Tcr2 Therapeutics. Please utilize our Beneish M Score to check the likelihood of Tcr2 Therapeutics' management manipulating its earnings.
| 14th of August 2023 Upcoming Quarterly Report | View | |
| 14th of November 2023 Next Financial Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 31st of March 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Tcr2 Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |